Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 8-K (Current Report)
Report Date: July 29, 2026
Reporting Period: Second Quarter ended June 30, 2026
This filing serves as a notification that the Company issued a press release announcing its financial results for the quarter ended June 30, 2026. The detailed results are incorporated by reference via Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The filing states that revenue, profit, cash flow, margins, debt, and liquidity figures are contained within the press release (Exhibit 99.1) but are not listed in this document.
Material Changes
No material changes or comparative financial data are disclosed in the text of this Form 8-K. Investors must refer to the attached press release for year-over-year or quarter-over-quarter comparisons.
Guidance, Outlook, and Risks
The text does not provide specific guidance, management commentary, risk factors, or details on contingencies. These items are referenced as being part of the press release furnished as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 ("Teva Reports 2026 Second Quarter Financial Results") for actual revenue, net income, and cash flow figures.
- Verify the specific details of the press release regarding any changes in guidance or strategic outlook.
- Confirm the impact of any unusual items or contingencies mentioned in the full press release.
- Check the Interactive Data File (Exhibit 104) for granular financial data embedded in Inline XBRL.